Lucid Diagnostics (LUCD) Maxim Group’s 2024 Healthcare Virtual Summit summary

Conference overview

• Fifth annual virtual conference featuring over 85 companies, with a focus on diagnostics and early cancer detection technologies.

• Emphasis on the importance of early and pre-cancer screening to reduce mortality and healthcare costs.

• Lucid Diagnostics presented its commercial-stage technologies, EsoGuard and EsoCheck, for esophageal cancer screening.

Market need and technology

• Esophageal cancer has a high mortality rate, with most cases diagnosed too late for effective intervention.

• Less than 5% of at-risk patients undergo the current gold standard, upper endoscopy, highlighting a significant unmet need.

• EsoGuard and EsoCheck enable office-based, minimally invasive, and well-tolerated pre-cancer screening.

• The test targets high-risk populations based on updated GI society guidelines, focusing on GERD and additional risk factors.

Awareness and commercial strategy

• Awareness campaigns include CheckYourFoodTube.com, direct outreach to GIs, primary care, and innovative mobile test centers.

• Commercial activities are currently limited by reimbursement, with 2,500–3,000 tests per quarter and $6–$7 million in quarterly claim submissions.

• Direct contracting with self-insured employers and cash pay through concierge medicine are growing revenue streams.

• Special events target high-risk groups, such as first responders, and mobile centers increase access.